Skip to content

The PERCEIVE Study

Prediction of Risk and Communication of Outcome Following Major Lower Limb Amputation - a Collaborative Study (PERCEIVE). A Multi-methods Study of Risk Perception, Communication and the Extent and Experiences of Shared Decision Making Around the Time of Major Lower Limb Amputation.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04903756
Acronym
PERCEIVE
Enrollment
30
Registered
2021-05-27
Start date
2020-10-01
Completion date
2022-12-20
Last updated
2025-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amputation, Diabetes Mellitus, Peripheral Artery Disease

Keywords

Major lower limb amputation, Risk perception, Shared decision making

Brief summary

The PERCEIVE (PrEdiction of Risk and Communication of outcomE followIng major lower limb amputation - a collaboratiVE study) study aims to explore how decisions about major lower limb amputations are made by patients and healthcare professionals.

Detailed description

This study will look in detail at major lower limb amputation risk perception, communication and decision-making, both from a patient/family and a surgeon/clinician point of view. The investigators will audio-record 10-15 consultations between surgeons and patients, examining the communication and decision-making process, and conduct individual interviews with 10-15 patients and 10-15 healthcare professionals. Patients will be interviewed at two time points: firstly as soon as possible after they discuss the possibility of leg amputation with a surgeon, and secondly around six months later. The investigators will identify what is important to patients, what information they need to make an informed decision and how best to communicate that information. Interviews with surgeons, anaesthetists and specialist physiotherapists will explore how they estimate risks and outcomes of amputation surgery, and how they communicate this to patients. Finally, the investigators will combine all this information together and discuss our findings with groups of patients and healthcare professionals, to identify key areas around amputation decision-making that can be improved and how best to further examine those areas.

Interventions

None listed

Sponsors

Health and Care Research Wales
CollaboratorUNKNOWN
Aneurin Bevan University Health Board
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any patient aged 18 years old or over with chronic limb threatening ischaemia or diabetic foot disease for whom major lower limb amputation is considered or discussed * Vascular surgeons / anaesthetists / specialist physiotherapists involved in, or supporting major lower limb amputation decision making

Exclusion criteria

* Patients under 18 years old * Patients undergoing major lower limb amputation for other causes (e.g. trauma or cancer) * Any patient/healthcare professional unable or unwilling to provide informed consent. Some patients undergoing emergency major lower limb amputation will have insufficient time to give informed consent * Potential participants with an insufficient understanding of English or Welsh to be able to provide informed consent * Potential participants unable to complete an interview in English

Design outcomes

Primary

MeasureTime frameDescription
Analysis of audio-recorded consultations between surgeons and patients.During primary consultationTheme-oriented discourse analysis

Secondary

MeasureTime frameDescription
Analysis of patient interviewsAs soon as possible after the time of consultation and approximately 6 months following consultationThematic analysis of interview transcripts
Analysis of healthcare professional interviewsAs soon as possible after the time of consultationThematic analysis of interview transcripts

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026